COMPUGEN LTD
CGEN evidence brief
What we can confirm
- BioSniper Score:
- 5.7 / 10
- Market Cap:
- $234.0M
What it means
What to watch
Prepared research question
What matters most for CGEN—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · CGEN
Compugen Ltd. (CGEN) is a clinical-stage cancer immunotherapy company that leverages AI/ML for drug target discovery and is advancing a pipeline of immuno-oncology assets, including the COM701 antibody in ovarian cancer and the partnered rilvegostomig program.
Key risk: Early-stage pipeline
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
$234.0M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Dec 31, 2025.
Tracking 3 clinical trials for COMPUGEN LTD.
Compugen Ltd. (CGEN) is a clinical-stage cancer immunotherapy company that leverages AI/ML for drug target discovery and is advancing a pipeline of immuno-oncology assets, including the COM701 antibody in ovarian cancer and the partnered rilvegostomig program.
- Cash & equivalents of $90.6M and shareholders' equity of $102.7M as of 2025-12-31 [sec].
- Q1 2026 revenue of $2.18M with an EPS loss of -$0.08 [news · published 2026-05-18].
- COM701 MAIA-ovarian trial actively enrolling patients in the U.S., Israel, and France, with interim analysis expected in Q1 2027 [news · published 2026-05-18].
- Partner AstraZeneca is advancing the rilvegostomig program [news · published 2026-05-18].
- Non-dilutive royalty monetization agreement with AstraZeneca in December 2025 expected to extend cash runway into 2029 [news · published 2025-12-17].
What works
- Non-dilutive royalty monetization with AstraZeneca extends cash runway into 2029, supporting pipeline advancement [news · published 2025-12-17].
- AI/ML-powered discovery platform (UNIGEN) is being expanded into tumor-associated antigen research, potentially broadening the target pipeline [news · published 2026-10-05].
- Partnered program rilvegostomig is being advanced by AstraZeneca, providing external validation and potential future royalties [news · published 2026-05-18].
What to weigh
- The company remains pre-revenue from product sales, with Q1 2026 revenue of only $2.18M and an EPS loss of -$0.08 [news · published 2026-05-18].
- COM701 is still in early-stage clinical testing (Phase 1/2 adaptive platform trial), with no pivotal data yet [news · published 2026-06-18].
- Reliance on a single partnered program (rilvegostomig) for near-term monetization creates concentration risk [news · published 2025-12-17].
From the filings
Quoted directly from source documents.
COM701 MAIA-ovarian trial is enrolling and interim analysis is on track
“COM701 MAIA-ovarian trial actively enrolling patients across all clinical sites in the U.S., Israel, and France; interim analysis on track by Q1 2027”
News · May 18, 2026
Royalty monetization extends cash runway into 2029
“Non-dilutive strategic transaction expected to extend cash runway into 2029”
News · December 17, 2025
AI platform expansion into tumor-associated antigen research
“expansion of its AI-powered discovery platform into tumor-associated antigen, or TAA, research”
News · October 5, 2026
Catalyst timeline
- 2020-03-31 · Phase 1 start of COM902 — A Phase 1 study of COM902 in advanced malignancies began; this is an early-stage program.
- 2025-01-07 · Phase 1 start of COM503 — First-in-human Phase 1 trial of COM503 (anti-IL18BP antibody) initiated as monotherapy and in combination.
- 2025-07-21 · Phase 2 start of COM701 in ovarian cancer — Adaptive platform trial (MAIA) evaluating COM701 as maintenance therapy in platinum-sensitive ovarian cancer began.
Risks & what to watch (3)›
Key risks
- Early-stage pipeline — All internal programs are in Phase 1 or Phase 2, with no approved products or late-stage data [news · published 2026-06-18].
- Revenue concentration — Near-term monetization depends heavily on the partnered rilvegostomig program and royalty stream [news · published 2025-12-17].
- Clinical trial execution — COM701 trial is still enrolling; any delays could push interim analysis past Q1 2027 [news · published 2026-05-18].
What to watch
- Interim analysis of the COM701 MAIA-ovarian trial expected in Q1 2027 [news · published 2026-05-18].
- Progress of AstraZeneca's rilvegostomig program, which could trigger milestone or royalty payments [news · published 2026-05-18].
- Expansion of the UNIGEN AI platform into new target classes and any resulting preclinical candidates [news · published 2026-10-05].
- Cash runway trajectory and any additional non-dilutive financing or partnership deals [news · published 2025-12-17].
Sources: Catalysts · News · Generated October 11, 2026 · How we verify sources →
Run COMPUGEN LTD through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available COMPUGEN LTD facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
Pipeline inputs are unavailable for this score. It uses only the available signals shown below.
Cash runway data unavailable
D/E 0.52
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
0 buys · 3 sells (180d)
Regulatory
Financials
Short Interest
as of May 20, 2026- % of float
- 1.5%
- Days to cover
- 2.7
- Shares short
- 1,422,380
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
CGEN short interestFrequently asked questions
What is the AI investment thesis for COMPUGEN LTD?
Compugen Ltd. (CGEN) is a clinical-stage cancer immunotherapy company that leverages AI/ML for drug target discovery and is advancing a pipeline of immuno-oncology assets, including the COM701 antibody in ovarian cancer and the partnered rilvegostomig program.
Who is the CEO of COMPUGEN LTD?
Dr. Eran Ophir Ph.D. is the chief executive officer of COMPUGEN LTD (CGEN).
Where is COMPUGEN LTD headquartered?
COMPUGEN LTD (CGEN) is headquartered in Holon, Israel.
What therapeutic areas does COMPUGEN LTD focus on?
COMPUGEN LTD develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.